Table 2.
Variable | Group 1 (n = 28) | Group 2 (n = 28) | p |
---|---|---|---|
FRAP (mmol FeCl2 L−1) | 1.25 ± 0.23 | 1.15 ± 0.16 | NS |
Nu-FRAP (mmol FeCl2 L−1) | 0.43 ± 0.09 | 0.40 ± 0.05 | NS |
DPPH (% reduction) | 25.2 ± 5.7 | 22.1 ± 4.7 | <0.05 |
Nu-DPPH (% reduction) | 5.4 ± 1.5 | 5.7 ± 2.4 | NS |
FRAS (mmol FeCl2 L−1) | 6.81 ± 2.85 | 5.22 ± 2.11 | <0.05 |
Nu-FRAS (mmol FeCl2 L−1) | 1.58 ± 1.01 | 1.42 ± 0.69 | NS |
DPPHS (% reduction) | 27.6 ± 12.6 | 24.6 ± 12.8 | NS |
Nu-DPPHS (% reduction) | 5.7 ± 4.1 | 6.5 ± 5.2 | NS |
Data are presented as mean ± SD. Nu-FRAS—Non-urate Ferric Reducing Ability of Saliva; FRAS—Ferric Reducing Ability of Saliva; Nu-FRAP—Non-urate Ferric Reducing Ability of Plasma; FRAP—Ferric Reducing Ability of Plasma; Nu-DPPHS—Non-urate 2.2-diphenyl-1-picryl-hydrazyl test of saliva; DPPHS—2.2-diphenyl-1-picryl-hydrazyl test of saliva; Nu-DPPH—Non-urate 2.2-diphenyl-1-picryl-hydrazyl test of plasma; DPPH—2.2-diphenyl-1-picryl-hydrazyl test of plasma; NS—non-significant difference.